Immunotherapy offers hope for men with prostate cancer
A small number of men were "super responders" and remained well even after the trial ended.
Purpose of review The successful development of effective cancer immunotherapy, in particular immune checkpoint inhibitors, has changed the treatment paradigm of many tumor types. In light of the limited efficacy of checkpoint inhibitors demonstrated in recent clinical trials in refractory prostate cancer, this review highlights important recent and ongoing studies that are shaping the pursuit of effective immunotherapy for prostate cancer. Recent findings We review two overarching themes with respect to recent studies of prostate cancer immunotherapy: evolving therapeutic strategies and novel biological findings, inc...
Some historic breakthroughs have been made in immunotherapy of advanced cancer. However, there is still little research on immunotherapy in prostate cancer. We explored the relationship between immune cell inf...
(University of Colorado Anschutz Medical Campus) University of Colorado Cancer Center study suggests a new approach, or, possibly two new approaches against prostate cancer bone metastases: While targeted therapies and anti-cancer immunotherapies have not been especially successful against primary prostate cancers, the study suggests that both these approaches may be effective against the bone metastases that grow from primary prostate cancers, and, in fact, the type of bone metastasis may dictate which targeted therapies and immunotherapies work best.
In this study, we tested whether vaccinations with DCs, loaded with a PD-L1 immunogen (PDL1-Vax), are able to induce anti-PD-L1 immune responses. We found that DCs loaded with PDL1-Vax induced anti-PD-L1 antibody and T cell responses in immunized mice and that PD-L1-specific CTLs had cytolytic activities against PD-L1+ tumor cells. We demonstrated that vaccination with PDL1-Vax DCs potently inhibited the growth of PD-L1+ tumor cells. In summary, this study demonstrates for the first time the principle and feasibility of DC vaccination (PDL1-Vax) to actively induce anti-PD-L1 antibody and T cell responses capable of inhibit...
A small number of men with advanced prostate cancer respond very well to the immunotherapy drug pembrolizumab, according to a new study. Now scientists want to find out why.
PROSTATE CANCER is one of the most common forms of cancer in men, accounting for 44.4 percent of all cancers alongside lung, prostate and colorectal in 2018. A new immunotherapy drug has shown promise for prostate cancer sufferers in advanced stages of the disease.
One in 20 men with advanced unresponsive prostate cancer respond to immunotherapy in clinical trial Related items fromOnMedica Is crowdfunding for cancer patients paying for ‘quackery’? Cancer patients using complementary meds die sooner Men ’s dementia risk higher after androgen deprivation therapy Wales cancer spend at record high Only half of new cancer drugs extend or improve life
(Institute of Cancer Research) Some men with advanced prostate cancer who have exhausted all other treatment options could live for two years or more on immunotherapy, a major clinical trial has shown.Researchers found that a small proportion of men were 'super responders' and were alive and well even after the trial had ended despite having had a very poor prognosis before treatment.
A new radiomics technique can determine which lung cancer patients will benefit...Read more on AuntMinnie.comRelated Reading: AI, radiomics predict prostate cancer aggressiveness CT radiomics uses immunohistology to detect thyroid cancer AI can improve reproducibility of radiomics in CT Can radiomics detect pancreatic ductal adenocarcinoma? AI, radiomics can help predict chemotherapy response
CONCLUSIONS: Hypermutated MMRd metastatic prostate cancer is associated with oncogene activation and subclonal diversity, which may contribute to a clinically aggressive disposition in selected patients. In patients with detectable ctDNA, cell-free DNA sequencing is a practical tool to prioritize this subtype for immunotherapy. PMID: 31744831 [PubMed - as supplied by publisher]